HRS 9190
Alternative Names: HRS-9190Latest Information Update: 30 May 2025
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Musculoskeletal disorders
Most Recent Events
- 17 Apr 2025 Preclinical trials in Musculoskeletal disorders in China (Parenteral), prior to April 2025
- 17 Apr 2025 Jiangsu HengRui Medicine Co. plans a phase I trial for Musculoskeletal disorders (In adults, In volunteers) in China (Parenteral, Injection), in April 2025 (NCT06932315)